JP4298289B2 - Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド - Google Patents

Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド Download PDF

Info

Publication number
JP4298289B2
JP4298289B2 JP2002514149A JP2002514149A JP4298289B2 JP 4298289 B2 JP4298289 B2 JP 4298289B2 JP 2002514149 A JP2002514149 A JP 2002514149A JP 2002514149 A JP2002514149 A JP 2002514149A JP 4298289 B2 JP4298289 B2 JP 4298289B2
Authority
JP
Japan
Prior art keywords
embedded image
compound
conhch
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002514149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004504404A (ja
JP2004504404A5 (enExample
Inventor
アニル・ケイ・サクセナ
ビイヨール・モーピル・ギリジャバラバン
レイモンド・ジー・ラビー
エドウィン・イー・ジャオ
フランク・ベネット
ジンピン・エル・マコーミック
ハイヤン・ワン
ラッセル・イー・パイク
ステファン・エル・ボーゲン
ティン−ヤウ・チャン
イ−ツン・リュー
ジャオニン・ジュ
エフ・ジョージ・ヌジョローグ
アショック・アラサパン
テジャル・エヌ・パレク
アシット・ケイ・ガンガリー
ケビン・エックス・チェン
スリカント・ベンカトラマン
ヘンリー・エイ・バッカロ
パトリック・エイ・ピント
バマ・サンタナム
ワンリ・ウ
シスカ・ヘンドラタ
ユフア・ファン
スコット・ジェフリー・ケンプ
オディール・エスター・レビー
マルゲリータ・リム−ウィルビー
スーザン・ワイ・タムラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22822095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4298289(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004504404A publication Critical patent/JP2004504404A/ja
Publication of JP2004504404A5 publication Critical patent/JP2004504404A5/ja
Application granted granted Critical
Publication of JP4298289B2 publication Critical patent/JP4298289B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2002514149A 2000-07-21 2001-07-19 Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド Expired - Fee Related JP4298289B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22010800P 2000-07-21 2000-07-21
PCT/US2001/022678 WO2002008244A2 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008275159A Division JP2009051860A (ja) 2000-07-21 2008-10-27 Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Publications (3)

Publication Number Publication Date
JP2004504404A JP2004504404A (ja) 2004-02-12
JP2004504404A5 JP2004504404A5 (enExample) 2006-01-05
JP4298289B2 true JP4298289B2 (ja) 2009-07-15

Family

ID=22822095

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002514149A Expired - Fee Related JP4298289B2 (ja) 2000-07-21 2001-07-19 Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP2008275159A Pending JP2009051860A (ja) 2000-07-21 2008-10-27 Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP2012243691A Expired - Fee Related JP5775505B2 (ja) 2000-07-21 2012-11-05 Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008275159A Pending JP2009051860A (ja) 2000-07-21 2008-10-27 Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP2012243691A Expired - Fee Related JP5775505B2 (ja) 2000-07-21 2012-11-05 Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Country Status (31)

Country Link
US (4) US7012066B2 (enExample)
EP (1) EP1385870B1 (enExample)
JP (3) JP4298289B2 (enExample)
KR (2) KR100904788B1 (enExample)
CN (3) CN102372764A (enExample)
AR (2) AR033985A1 (enExample)
AT (1) ATE461207T1 (enExample)
AU (2) AU7698801A (enExample)
BR (1) BR0112540A (enExample)
CA (1) CA2410662C (enExample)
CY (2) CY1112267T1 (enExample)
CZ (1) CZ303213B6 (enExample)
DE (2) DE60141608D1 (enExample)
DK (1) DK1385870T3 (enExample)
EC (1) ECSP034438A (enExample)
ES (1) ES2341534T3 (enExample)
HU (1) HU229997B1 (enExample)
IL (2) IL153670A0 (enExample)
LU (1) LU91910I2 (enExample)
MX (1) MXPA03000627A (enExample)
MY (2) MY143322A (enExample)
NO (2) NO332329B1 (enExample)
NZ (1) NZ523782A (enExample)
PL (1) PL206255B1 (enExample)
PT (1) PT1385870E (enExample)
RU (2) RU2355700C9 (enExample)
SI (1) SI1385870T1 (enExample)
SK (1) SK288064B6 (enExample)
TW (1) TWI324611B (enExample)
WO (1) WO2002008244A2 (enExample)
ZA (1) ZA200210312B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009051860A (ja) * 2000-07-21 2009-03-12 Schering Corp Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Families Citing this family (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
AU3659102A (en) * 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
KR100926244B1 (ko) 2001-07-11 2009-11-12 버텍스 파마슈티칼스 인코포레이티드 브릿지된 바이사이클릭 세린 프로테아제 억제제
MXPA04003825A (es) * 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
MXPA04007163A (es) 2002-01-23 2004-10-29 Schering Corp Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c.
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
EP1497282A2 (en) * 2002-04-11 2005-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
US20050090450A1 (en) 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
SG185140A1 (en) * 2003-06-17 2012-11-29 Merck Sharp & Dohme Enantiomer forms of boc protected 3-amino-3-cyclobutylmethyl-2-hydroxy-propionamide
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
JP4825129B2 (ja) * 2003-06-17 2011-11-30 シェーリング コーポレイション （１ｒ，２ｓ，５ｓ）−６，６−ジメチル−３−アザビシクロ［３，１，０］ヘキサン−２−カルボキシレートまたはその塩の調製のためのプロセスおよび中間体
US7109172B2 (en) 2003-07-18 2006-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA06002250A (es) * 2003-08-26 2006-05-17 Schering Corp Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c.
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1664091A1 (en) * 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1673385B1 (en) 2003-09-22 2011-03-02 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
CN1894274A (zh) 2003-09-26 2007-01-10 先灵公司 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
ES2389201T3 (es) 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
MXPA06005683A (es) 2003-11-20 2006-12-14 Schering Corp Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
KR20060118532A (ko) * 2003-12-11 2006-11-23 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ３／ｎｓ４ａ 세린 프로테아제의억제제
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
ES2336009T3 (es) * 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
EP1711515A2 (en) * 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2006134002A (ru) * 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
EP1742914A1 (en) * 2004-02-27 2007-01-17 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
CN1950393A (zh) 2004-02-27 2007-04-18 先灵公司 丙型肝炎病毒ns3蛋白酶的抑制剂
RU2006134005A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
US7173057B2 (en) 2004-02-27 2007-02-06 Schering Corporation Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus
RU2428428C9 (ru) * 2004-02-27 2012-03-10 Шеринг Корпорейшн Серусодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
ATE438622T1 (de) 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
WO2005107745A1 (en) * 2004-05-06 2005-11-17 Schering Corporation An inhibitor of hepatitis c
CN1984922A (zh) 2004-05-20 2007-06-20 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US20080267915A1 (en) 2004-10-01 2008-10-30 Vertex Pharmaceuticals Hcv Ns3-Ns4a Protease Inhibition
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
GB0426661D0 (en) * 2004-12-06 2005-01-05 Isis Innovation Pyrrolidine compounds
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US7772178B2 (en) 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
JP2008545748A (ja) * 2005-06-02 2008-12-18 シェーリング コーポレイション Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060276405A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
CN101242816B (zh) * 2005-06-30 2012-10-31 维罗贝股份有限公司 Hcv抑制剂
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP2305696A3 (en) * 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
BRPI0614637A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos do vìrus da hepatite c
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
ES2401661T3 (es) * 2005-08-02 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas
RU2446171C2 (ru) 2005-08-19 2012-03-27 Вертекс Фармасьютикалз Инкорпорейтед Способы и промежуточные продукты
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
WO2007041631A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
NZ568324A (en) 2005-11-11 2012-01-12 Vertex Pharma Hepatitis C virus variants
AR056805A1 (es) * 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
CN101384551B (zh) * 2005-12-22 2012-08-29 先灵公司 制备6,6-二甲基-3-氮杂双环-[3.1.0]-己烷化合物和其对映体盐的方法
US7622496B2 (en) 2005-12-23 2009-11-24 Zealand Pharma A/S Modified lysine-mimetic compounds
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
MX2008010355A (es) * 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
AR059430A1 (es) * 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP2009528353A (ja) * 2006-03-03 2009-08-06 シェーリング コーポレイション Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ
CA2645684A1 (en) * 2006-03-06 2007-09-13 Abbott Laboratories Compositions and methods of use of ritonavir for treating hcv
JP2009531315A (ja) 2006-03-16 2009-09-03 バーテックス ファーマシューティカルズ インコーポレイテッド 重水素化ｃ型肝炎プロテアーゼインヒビター
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
JP2009536158A (ja) * 2006-04-11 2009-10-08 ノバルティス アクチエンゲゼルシャフト Ｈｃｖ阻害剤
EP2518079A3 (en) 2006-04-11 2012-12-12 Novartis AG HCV/HIV inhibitors and their uses
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
EP2027143A2 (en) 2006-05-23 2009-02-25 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2019837B1 (en) * 2006-05-23 2011-03-23 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008019477A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
CA2663159A1 (en) * 2006-09-13 2008-03-20 Novartis Ag Organic compounds and their uses
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
JP2010510246A (ja) * 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
EP2097405A2 (en) * 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
WO2008076316A2 (en) * 2006-12-15 2008-06-26 Schering Corporation Bisulfite purification of an alpha-keto amide
CN101611000B (zh) * 2006-12-20 2013-08-21 默沙东公司 (1r,2s,5s)-n-[(1s)-3-氨基-1-(环丁基甲基)-2,3-二氧代丙基]-3-[(2s)-2-[[[(1,1-二甲基乙基)氨基]-羰基]氨基]-3,3-二甲基-1-氧代丁基]-6,6-二甲基-3-氮杂双环[3.1.0]己烷-2-碳酰胺的制备方法
ES2558856T3 (es) 2006-12-21 2016-02-09 Zealand Pharma A/S Síntesis de compuestos de pirrolidina
KR20090106539A (ko) * 2006-12-22 2009-10-09 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
JP5079818B2 (ja) 2006-12-22 2012-11-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
JP5055377B2 (ja) 2006-12-22 2012-10-24 シェーリング コーポレイション ［５，６−環］環形成インドール誘導体およびその使用方法
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
CA2677487A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
EA200970806A1 (ru) * 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
US8575208B2 (en) * 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2139854A2 (en) * 2007-03-23 2010-01-06 Schering Corporation P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
WO2008137779A2 (en) * 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
CA2686546A1 (en) * 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009032124A1 (en) * 2007-08-29 2009-03-12 Schering Corporation Substituted indole derivatives and methods of use thereof
EP2195317B1 (en) 2007-08-29 2012-01-18 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
RU2010111550A (ru) * 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) 2,3-замещенные индольные производные для лечения вирусных инфекций
EP2436682A1 (en) 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CA2699280A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
KR101396696B1 (ko) * 2007-10-10 2014-05-16 노파르티스 아게 스피로피롤리딘, 및 ｈｃｖ 및 ｈｉｖ 감염에 대한 그의 용도
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
CN102317285A (zh) * 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
JP2011504929A (ja) * 2007-11-28 2011-02-17 シェーリング コーポレイション ６，６−ジメチル−３−アザビシクロ［３．１．０］ヘキサンを提供するのに有用な中間体調製のための脱塩化水素化プロセス
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
AR071270A1 (es) * 2007-12-21 2010-06-09 Schering Corp Proceso para la sintesis de 3- amino-3 ciclobutilmetil -2- hidroxipropionamida y uso del mismo
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
RU2490272C2 (ru) * 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
JP5580814B2 (ja) * 2008-06-13 2014-08-27 メルク・シャープ・アンド・ドーム・コーポレーション ３環式インドール誘導体およびその使用方法
EP2481737A1 (en) 2008-06-24 2012-08-01 Merck Sharp & Dohme Corp. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2010022128A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010045266A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
KR20110116136A (ko) 2009-01-07 2011-10-25 싸이넥시스, 인크. Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
TW201105323A (en) 2009-06-23 2011-02-16 Gilead Sciences Inc Pharmaceutical compositions useful for treating HCV
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
WO2011031904A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
CN105001302A (zh) * 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US20120329704A1 (en) * 2010-02-25 2012-12-27 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patieentenzorg Process for the preparation of substituted prolyl peptides and similar peptidomimetics
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013072327A1 (en) 2011-11-14 2013-05-23 Sanofi Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013178682A2 (en) * 2012-05-30 2013-12-05 Chemo Ibérica, S.A. Multicomponent process for the preparation of bicyclic compounds
CN103508918B (zh) * 2012-06-18 2015-09-09 上海医药工业研究院 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014061034A1 (en) * 2012-10-18 2014-04-24 Msn Laboratories Limited Process for preparation of boceprevir and intermediates thereof
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014083575A2 (en) 2012-11-29 2014-06-05 Mylan Laboratories Ltd Improved process for the preparation of boceprevir intermediate
CN103936627B (zh) * 2013-01-18 2016-08-31 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅶ及其制备方法和应用
CN103936652B (zh) * 2013-01-18 2016-07-06 上海医药工业研究院 抗丙肝药物Boceprevir的中间体IV及其制备方法和应用
CN103936818B (zh) * 2013-01-18 2017-09-29 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅰ及其制备方法和应用
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
SG11201507106PA (en) 2013-03-14 2015-10-29 Onyx Therapeutics Inc Dipeptide and tripeptide epoxy ketone protease inhibitors
AR095426A1 (es) * 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CN103387510B (zh) * 2013-08-08 2015-09-09 苏州永健生物医药有限公司 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10035760B2 (en) * 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN106810485A (zh) * 2015-11-27 2017-06-09 上海现代制药股份有限公司 一种手性联苯吡咯烷酮的制备方法及其中间体
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP7179721B2 (ja) * 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体
JP7164521B2 (ja) * 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
BR112018076766A2 (pt) * 2016-06-21 2019-04-02 Orion Ophthalmology LLC derivados de prolinamida alifática
WO2018032467A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
WO2018032468A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
US20190359589A1 (en) 2017-01-23 2019-11-28 Basf Se Fungicidal pyridine compounds
CN110475772A (zh) 2017-04-06 2019-11-19 巴斯夫欧洲公司 吡啶化合物
ES2870106T3 (es) 2017-05-05 2021-10-26 Zealand Pharma As Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
WO2020169593A1 (en) 2019-02-19 2020-08-27 Univerza V Ljubljani Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
EP4635972A3 (en) * 2020-07-20 2025-12-24 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2022109360A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US12540141B2 (en) 2020-11-23 2026-02-03 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CA3213008A1 (en) * 2021-04-01 2022-10-06 Miles Stuart Congreve Sars-cov-2 mpro inhibitor compounds
RS66213B1 (sr) * 2021-04-16 2024-12-31 Fujian Akeylink Biotechnology Co Ltd Jedinjenje kratkog peptida prolina modifikovanog prstenom i upotreba istog
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023107417A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
CN114133350B (zh) * 2021-12-16 2023-05-23 浙江乐普药业股份有限公司 一种抗新冠药物Paxlovid中间体的制备方法
WO2023149981A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars
US12145942B2 (en) 2022-04-05 2024-11-19 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN114736151B (zh) * 2022-04-13 2023-04-21 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德关键中间体制备方法及化合物的结构式
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
CN115160205B (zh) * 2022-07-08 2024-06-07 上海皓鸿生物医药科技有限公司 一种制备(s)-1-(叔丁氧羰基)-2,5-二氢-1h-吡咯-2-羧酸及盐的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177134B (en) * 1977-07-18 1981-07-28 Richter Gedeon Vegyeszet Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity
DE2936099A1 (de) * 1979-09-06 1981-04-02 Victor Dipl.- Chem. 8000 München Brantl Pharmakologisch aktive peptide
JPS5781447A (en) * 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
ATE132182T1 (de) 1989-02-01 1996-01-15 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche zusammensetzung auf der basis von chlorfluorkohlenwasserstoffen
US5359138A (en) 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
EP0672648B1 (en) 1989-04-15 1998-09-23 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Threo (2R,3S)-3-amino-2-hydroxypentanoic acid and threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentanoic acid
AU7675491A (en) 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
JP2804817B2 (ja) 1990-04-13 1998-09-30 財団法人微生物化学研究会 ３―アミノ―２―オキソ脂肪酸誘導体の製造法
JPH04149166A (ja) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd 新規ケト酸アミド誘導体
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
FR2686086A1 (fr) * 1992-01-15 1993-07-16 Adir Nouveaux derives de peptides et de pseudopeptides therapeutiquement actifs dans la cascade de coagulation sanguine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU666176B2 (en) 1992-01-31 1996-02-01 Abbott Laboratories Mammalian expression systems for HCV proteins
AU4544993A (en) 1992-06-24 1994-01-24 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5514694A (en) 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
US5414018A (en) 1993-09-24 1995-05-09 G. D. Searle & Co. Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension
US5843450A (en) 1994-02-14 1998-12-01 Abbott Laboratories Hepatitis GB Virus synthetic peptides and uses thereof
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5500208A (en) 1994-06-07 1996-03-19 The Procter & Gamble Company Oral compositions comprising a novel tripeptide
US6285380B1 (en) * 1994-08-02 2001-09-04 New York University Method and system for scripting interactive animated actors
RU2104284C1 (ru) * 1994-10-20 1998-02-10 Научно-исследовательский институт вирусологии им.Д.И.Ивановского РАМН Синтетические олигопептиды, специфически взаимодействующие с антителами к вирусу гепатита с, способы диагностики hcv-инфекции (варианты)
US5843752A (en) 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5919765A (en) 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5763576A (en) 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
WO1998007734A1 (en) 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
IT1285158B1 (it) 1996-09-17 1998-06-03 Angeletti P Ist Richerche Bio Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
ATE229066T1 (de) 1996-09-24 2002-12-15 Procter & Gamble Flüssige reinigungsmittel, die proteolytisches enzym, peptidaldehyd und eine borsäurequelle enthalten
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6291640B1 (en) 1996-12-27 2001-09-18 Boehringer Ingelheim Ltd. Peptidomimetic inhibitors of the human cytomegalovirus protease
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
PT1012180E (pt) * 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2000256396A (ja) 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU2055301A (en) * 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009051860A (ja) * 2000-07-21 2009-03-12 Schering Corp Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Also Published As

Publication number Publication date
HU229997B1 (hu) 2015-04-28
IL153670A (en) 2012-06-28
WO2002008244A3 (en) 2003-06-19
ES2341534T3 (es) 2010-06-22
NO20030272D0 (no) 2003-01-20
ATE461207T1 (de) 2010-04-15
NO20030272L (no) 2003-03-21
WO2002008244A2 (en) 2002-01-31
KR100939155B1 (ko) 2010-01-28
CN102206247A (zh) 2011-10-05
CA2410662A1 (en) 2002-01-31
USRE43298E1 (en) 2012-04-03
EP1385870A2 (en) 2004-02-04
PT1385870E (pt) 2010-06-07
HUP0401730A3 (en) 2012-09-28
US20060205672A1 (en) 2006-09-14
MY143322A (en) 2011-04-15
CN102206247B (zh) 2013-03-27
RU2355700C9 (ru) 2010-03-20
MXPA03000627A (es) 2004-07-30
ECSP034438A (es) 2003-03-10
SI1385870T1 (sl) 2010-08-31
MY139078A (en) 2009-08-28
SK752003A3 (en) 2003-08-05
JP5775505B2 (ja) 2015-09-09
CN1498224A (zh) 2004-05-19
HK1058047A1 (en) 2004-04-30
CY2011020I1 (el) 2016-12-14
DE122012000004I1 (de) 2012-04-26
NO2013003I2 (no) 2017-01-16
AR069373A2 (es) 2010-01-20
KR20030025277A (ko) 2003-03-28
ZA200210312B (en) 2004-03-29
US20030216325A1 (en) 2003-11-20
RU2355700C2 (ru) 2009-05-20
CA2410662C (en) 2012-09-18
US20110117057A1 (en) 2011-05-19
AR033985A1 (es) 2004-01-21
PL366063A1 (en) 2005-01-24
CY2011020I2 (el) 2016-12-14
AU2001276988B2 (en) 2007-01-25
PL206255B1 (pl) 2010-07-30
NO2013003I1 (no) 2013-03-04
SK288064B6 (sk) 2013-04-03
CZ303213B6 (cs) 2012-05-23
EP1385870B1 (en) 2010-03-17
JP2004504404A (ja) 2004-02-12
CZ2003151A3 (cs) 2003-05-14
TWI324611B (en) 2010-05-11
HUP0401730A2 (hu) 2004-12-28
NO332329B1 (no) 2012-09-03
IL153670A0 (en) 2003-07-06
KR20090030330A (ko) 2009-03-24
LU91910I2 (fr) 2012-02-02
US20040254117A9 (en) 2004-12-16
DE60141608D1 (de) 2010-04-29
KR100904788B1 (ko) 2009-06-25
BR0112540A (pt) 2003-06-24
CY1112267T1 (el) 2015-12-09
RU2008126266A (ru) 2010-01-10
JP2009051860A (ja) 2009-03-12
US7012066B2 (en) 2006-03-14
DK1385870T3 (da) 2010-07-05
JP2013032389A (ja) 2013-02-14
CN102372764A (zh) 2012-03-14
AU7698801A (en) 2002-02-05
NZ523782A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
JP5775505B2 (ja) Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP4563033B2 (ja) Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP4452441B2 (ja) Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP4748912B2 (ja) アルキルおよびアリールアラニンｐ２部分を含むｃ型肝炎ウイルスに対する大員環ｎｓ３−セリンプロテアーゼ阻害剤
US6800434B2 (en) Peptides as NS3-serine protease inhibitors of hepatitis C virus
US20050249702A1 (en) (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
AU2001276988A1 (en) Peptides as NS3-serine protease inhibitors of hepatitis C virus
ES2344890T3 (es) Nuevos peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
HK1058047B (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
HK1144439A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040817

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080929

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20081118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090407

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090415

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120424

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120424

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130424

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130424

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140424

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees